medigraphic.com
ISSN 1561-3119 (Electronic)

2017, Number S1

<< Back Next >>

Rev Cubana Pediatr 2017; 89 (S1)

Bacterial meningoencephalitis in a population younger tan 18 years

Donatién RNC, Gonzáles FN, Malfrán GM, Rondón RLE, Rondón PBI

Language: Spanish
References: 21
Page: 77-85
PDF size: 91.86 Kb.


ABSTRACT

Introduction: bacterial meningoencephalitis is a worldwide distributed disease affecting individuals of all ages, but mainly children.
Objective: to characterize epidemiological aspects of bacterial meningoencephalitis in patients admitted to "Juan de la Cruz Martinez Maceira" northern teaching pediatric hospital in Santiago de Cuba province.
Methods: cross-sectional, descriptive and observational study was performed by using the report of patients notified to the statistical department of the northern pediatric hospital with a diagnosis of bacterial meningitis and isolated microorganism in a population younger than 18 years of age. They were admitted to the hospital in the period of January 1st 2009 to December 31 2015 and the total number was 37 patients.
Results: the most affected age group was the one younger than 3 months. The most frequently identified microorganisms were group B hemolytic beta Streptococcus in 11 patients aged less than 3 months; and Streptococcus pneumoniae in 10 patients aged 3 months to 5 years. The group B hemolytic beta Streptococcus was the most lethal isolated microorganism in our institution. The fatality rate of bacterial meningoencephalitis was 24.4 % and the most affect age group was infants younger than 3 months.
Conclusions: future studies will allow delving into the epidemiology of these infections and to monitoring the changes that occur as a result of interventions.


REFERENCES

  1. Climent Y, Urwin R, Yero D, Martínez I, Martín A, Sotolongo F, et al. The genetic structure of Neisseria meningitides populations in Cuba before and after the introduction of a sero group BC vaccine. Infect Genet Evol. 2010;10:546-54.

  2. Holst J, Martín D, Arnold R, Huergo CC, Oster P, O'Hallahan J, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine. 2009;27(supp 2):B3-12.

  3. Dorta Contreras AJ, Noris García E, Bu-Coifiu Fanego R, Padilla Docal B. Bases moleculares de la Neuroinmunología. Barrera sangre-líquido cefalorraquídeo y síntesis intratecal de inmunoglobulinas. Rev Cubana Pediatr [serie en Internet]. 2005 [citado 12 de Enero de 2016];77(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034- 75312005000300006&lng=es&nrm=iso&tlng=es

  4. Padilla-Docal B, Dorta-Contreras AJ, Bu-Coifiu-Fanego R, Rodríguez-Rey A. C4CSF/serum quotient graphs for the evaluation of intrathecal C4 synthesis cerebrospinal fluid. Research. 2009;6:8.

  5. Sáfadi MA, Cintra OA. Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention. Neurol Res. 2010 Apr;32(3):263-71.

  6. Dorta Contreras AJ, Nuñez N, Pérez O. Neuroinmunología de la meningoencefalitis por Neisseria meningitidis. En: Dorta Conteras AJ, Bu Coifiu-Fanego R, Magraner Tarrau ME, Montoro Cardoso E, Nuñez Fernándes FA, Fundora Hernández H. Neuroinmunología Clínica. Ciudad de La Habana: Editorial Academia; 2009. p. 11-5.

  7. Lejon V, Robays J, N'Siesi FX, Mumba D, Hoogstoel A, Bisser S, et al. Treatment failure related to intrathecal immunoglobulin M (IgM) synthesis, cerebrospinal fluid IgM, and interleukin-10 in patients with hemolymphatic-stage sleeping sickness. Clin Vacc Immunol. 2007;14:732-7.

  8. Padilla Docal B, Dorta Contreras AJ, Bu Coifiu Fanego R, Noris García E, Fundora Hernández H, Callol Barroso J, et al. Síntesis intratecal de C3c e inmunoglobulinas en niños con meningoencefalitis bacteriana. Vacci Monitor. 2008;17(3):1-5.

  9. Black RE, Cousens S, Johnson HL, Lawn JE. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet. 2010;375(9730):1969-87.

  10. Valenzuela MT, O'Loughlin R, De la Hoz F, Gomez E. The burden of pneumococcal disease among Latin American and Caribbean children: review of the evidence. Rev Panam Salud Publica. 2009;25(3):270-9.

  11. Huwendiek S, Steiner T, Tönshoff B. When should you suspect meningitis? MMW Fortschr Med. 2007;149(2):15-8.

  12. Davenport MC, Del Valle MP, Gallegos P, Kannemann AL, Bokser VS. Bacterial meningitis: risk factors for development of acute complications. Arch Argent Pediatr [serie en Internet]. 2007 Oct [citado 20 de Septiembre de 2016];105(5). Disponible en: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0325- 00752007000500006&lng=es

  13. Dickinson Meneses FO, Pérez Rodríguez AE. Las meningoencefalitis bacterianas en la población infantil cubana: 1998-2000. Rev Cubana Pediatr [serie en Internet]. 2002 [citado 12 de Enero de 2016];74(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034- 75312002000200002&lng=es&nrm=iso&tlng=es

  14. Giglio N, Micone P, Venosa M, Carosella M, Gentile A, Cané A. Preferences in Argentine population for health states prevented by pneumococcal conjugate vaccine. 6th Congr on Vaccines, Immunization and immunotherapy, Milan. 2008;25(2):210-9.

  15. Sinha A, Constenla D, Valencia JE, O'Loughlin R, Gomez E, de la Hoz F, et al. Cost effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis. Rev Panam Salud Pública. 2008;24(5):304-13.

  16. OPS. Informe Regional de SIREVA II, 2011. Datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis en procesos invasores. Documentos técnicos. Regulaciones Sanitarias Internacionales, Alerta y Respuesta y Enfermedades Epidémicas (HSD/IR) [homepage en Internet]; Washington, D.C., OPS, 2011 [citado 12 de Marzo de 2014]. Disponible en: http://bases.bireme.br/cgibin/ wxislind.exe/iah/online/?IsisScript=iah/iah.xis&src=google&base=LILACS&lang=p &nextAction=lnk&exprSearch=682695& indexSearch=ID#top

  17. Arguedas A, Soley C, Abdelnour A. Prevenar experience. Vaccine. 2011;29(suppl 3):C26-34.

  18. Fitzwater SP, Chandran A, Santosham M, Johnson HL. The worldwide impact of the seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2012;31(5):501-8.

  19. Programa Nacional de Control de Enfermedades Inmunoprevenibles. Ministerio de Salud. Presidencia de la Nación. Introducción de la vacuna conjugada contra neumococo al Calendario Nacional de Inmunizaciones de la República Argentina. Lineamientos técnicos [homepage en Internet]; Argentina, 2011 [citado 12 de Marzo de 2014]. Disponible en: http://www.msal.gov.ar/neumococo/descargas/lineamientos-neumococo-25-11- 2011.pdf

  20. Pérez GM, Parra A, Casimir L, Mastroiani A. Infecciones invasivas por Streptococcus pneumoniae en un hospital pediátrico de tercer nivel antes de la introducción de la vacuna conjugada. Características clínicas y serotipos involucrados. Arch Argent Pediatr. 2013;111(3):202-5.

  21. Reijtman V, Fossati S, Hernández C, Sommerfieck P. Serotype distribution of pneumococci isolated from pediatric patients with acute otitis media and invasive infections, and potential coverage of pneumococcal conjugated vaccines. Rev Argent Microbiol. 2013;45(1):27-33.




2020     |     www.medigraphic.com